Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies
Michael Levy, Alan R Haycox, Ursula Becker et al. · Multiple Sclerosis and Related Disorders · 2021
BACKGROUND: To date, no specific scales have been developed to explore the impact of neuromyelitis optica spectrum disorder (NMOSD)-related disability on quality of life (QoL). The Expanded Disability Status Scale (EDSS) and the EuroQol 5-dimensions (EQ-5D) have been used to assess disability and QoL, respectively, in patients with NMOSD. However, there is limited evidence surrounding their use in this condition. We compared EDSS and EQ-5D data across two clinical trials to quantify the relationship between disability and QoL in patients with NMOSD. METHODS: SAkuraSky (NCT02028884) and SAkuraStar (NCT02073279) were Phase 3, multicenter, randomized, international, double-blind, placebo-controlled, parallel-assignment studies of satralizumab, administered in combination with baseline immunosuppressants (SAkuraSky) or as monotherapy (SAkuraStar). EDSS and EQ-5D were assessed at baseline and at 24-week intervals thereafter. The relationship between disability and QoL was assessed by estimating EQ-5D utilities (UK tariff) for each incremental EDSS category. A repeated-measures linear model was used to regress health utilities on EDSS score-derived health states. RESULTS: Overall, 176 patients underwent at least one EDSS assessment and completed an EQ-5D survey and were included in this analysis. There was a clear association between mean EQ-5D score and EDSS score, with decreases in QoL being observed at each incremental increase in disability. The relationship between EDSS and EQ-5D score remained consistent across the different treatment groups. CONCLUSIONS: These results, generated from high-quality clinical trial data, demonstrated a strong and consistent relationship between disability and QoL in patients with NMOSD.
Cited by 16 works. doi:10.1016/j.msard.2021.103332
Authors
- Michael Levy
- Alan R Haycox
- Ursula Becker
- Cristina Costantino
- Elisabetta Damonte
- Gaëlle Klingelschmitt
- H.-Christian von Büdingen
- Gene V. Wallenstein
- Lech Szczechowski
References
- Rating neurologic impairment in multiple sclerosis
- Modeling Valuations for EuroQol Health States
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
- Revised diagnostic criteria for neuromyelitis optica
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
- IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
- Estimating an EQ‐5D population value set: the case of Japan
- EQ-5D and the EuroQol Group: Past, Present and Future
- Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
- The psychometric properties of clinical rating scales used in multiple sclerosis